



## (51) International Patent Classification:

A61K 31/365 (2006.01) A61K 36/19 (2006.01)

## (21) International Application Number:

PCT/US2017/036463

## (22) International Filing Date:

08 June 2017 (08.06.2017)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/347,218 08 June 2016 (08.06.2016) US

(71) Applicant: INNOBIOSCIENCES, LLC [US/US]; 1303 Riverview Circle, Nw, Bradenton, FL 34209 (US).

(71) Applicant (for US only): PHARMACEUTICAL PATENT ATTORNEYS, LLC [US/US]; 55 Madison Avenue, 4th Floor, Morristown, NJ 07960-7397 (US).

(72) Inventor: HANCKE, Juan, O.; Instituto De Farmacologia, Facultad De Ciencias Veterinarias, Universidad Austral De Chile, Valdivia (CL).

(74) Common Representative: PHARMACEUTICAL PATENT ATTORNEYS, LLC; 55 Madison Avenue, 4th Floor, Morristown, NJ 07960-7397 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANDROGRAPHOLIDE TREATS PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS




FIGURE 6

(57) Abstract: Andrographolide 240 mg / day orally is the first treatment shown to significantly benefit progressive forms of Multiple Sclerosis in human patients.



**Declarations under Rule 4.17:**

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*

## 1 TITLE

2 *Andrographolide Treats Progressive Forms of Multiple Sclerosis*

## 3 RELATED APPLICATIONS

4 This application claims priority from United States Provisional patent application  
5 Serial No. 62/347218 (filed 08 June 2016), the contents of which is incorporated here by  
6 reference.

## 7 GOVERNMENT INTEREST

8 None.

## 9 PARTIES TO A JOINT RESEARCH AGREEMENT

10 Certain of this research has been conducted at Pontificia Universidad Catolica de  
11 Chile, pursuant to an agreement between Pontificia Universidad Catolica de Chile and the  
12 Applicant/ Assignee.

## 13 SEQUENCE LISTING

14 None.

## 15 PRIOR DISCLOSURES BY A JOINT INVENTOR

16 A joint inventor is co-author of Bertoglio, J.C. *et al.*, *Andrographis paniculata*  
17 *Decreases Fatigue In Patients With Relapsing-Remitting Multiple Sclerosis*, 16:77 BMC  
18 Neurology (23 May 2016).

## 19 BACKGROUND

20 Multiple Sclerosis (MS) is a chronic neuron-inflammatory demyelinating disorder of  
21 the Central Nervous System (CNS) that predominantly affects young adults in their 20s or  
22 40s and is one of the most common causes of non-traumatic disability among young and  
23 middle-aged people. MS-related health care costs are estimated to be more than \$10 billion  
24 annually in the United States, and \$15 billion worldwide.

25 As of 2008, between 2 and 2.5 million people are affected globally with rates varying  
26 widely in different regions of the world and among different populations. MS affects more  
27 than 350,000 people in the United States and 2.5 million worldwide. In the United States,  
28 prevalence estimates are approximately 90 per 100,000 population.

29 MS symptoms can start anywhere between 10 and 80 years of age, but they usually  
30 begin between 20 and 40 years, with a mean age of 32 years. Women outnumber men by a  
31 ratio of 2-3 to 1, although in Primary Progressive MS (PPMS) the ratio is closer to equal.

32 The name *multiple sclerosis* refers to scars (sclerae—better known as plaques or  
33 lesions) in particular in the white matter of the brain and spinal cord. The aetiology of MS is

1 unknown. It is believed to be an autoimmune disease, in which the body's immune system  
2 attacks its own tissues. In MS, this process destroys myelin, the fatty substance that coats and  
3 protects nerve fibres in the brain and spinal cord. When myelin is damaged, the messages that  
4 travel along that nerve may be slowed or blocked. MS is characterized by areas of  
5 demyelinated plaques disseminated throughout the CNS with a predilection for optic nerves,  
6 spinal cord, periventricular white matter (WM), corpus callosum, and cortical and sub-  
7 cortical grey matter (GM).

8 Later in the disease course, gradual progression of disability is observed. The overt  
9 progression of disability (secondary progressive MS) occurs when on-going irreversible  
10 tissue injury exceeds a critical threshold beyond which the nervous system can no longer  
11 compensate. At this point, the disease becomes essentially a degenerative process, with  
12 neurologic deterioration independent of on-going inflammation.

13 Multiple sclerosis is also known as “disseminated sclerosis” or “encephalomyelitis  
14 disseminate”. It is an inflammatory disease in which the insulating covers of nerve cells in  
15 the brain and spinal cord are damaged. This damage disrupts the ability of parts of the  
16 nervous system to communicate, resulting in a wide range of signs and symptoms, including  
17 physical, mental, and sometimes psychiatric problems.

18 While the cause is not clear, the underlying mechanism is thought to be either  
19 destruction by the immune system or failure of the myelin-producing cells. Proposed causes  
20 for this include genetics and environmental factors such as infections. MS is usually  
21 diagnosed based on the presenting signs and symptoms and the results of supporting medical  
22 tests.

23 MS can be classified by the comparative severity of symptoms over time. Where new  
24 symptoms occur in isolated attacks, this is termed the “relapsing-remitting” form of MS.  
25 Relapsing Remitting (RRMS) is the most common form of the disease (85% of patients),  
26 wherein symptoms appear for several days to weeks, after which they usually resolve  
27 spontaneously.

28 Where new symptoms build up or become more severe over time, this is termed a  
29 “progressive” form of MS. Between attacks, symptoms may disappear completely; however,  
30 permanent neurological problems often occur, especially as the disease advances. Patients  
31 with progressive forms of MS have a markedly worse clinical outlook than do patients with a  
32 relapsing-remitting form. The present invention relates to pharmaceutical compositions for  
33 treating progressive forms of MS, and more particularly to treating Secondary Progressive

1 (SP) and Primary Progressive (PP) forms of MS.

2 There is no known cure for multiple sclerosis. Treatments attempt to improve function  
3 after an attack and prevent new attacks. Medications used to treat MS while modestly  
4 effective can have adverse effects and be poorly tolerated. Many people pursue alternative  
5 treatments, despite a lack of evidence of efficacy. The long-term outcome is difficult to  
6 predict. Life expectancy is 5 to 10 years lower than that of an unaffected population. Above-  
7 average outcomes are more often seen in women, those who develop the disease early in life,  
8 and those who initially experienced few attacks. In the following paragraphs, an analysis is  
9 made of the 8 drugs that have been evaluated so far, in clinical trials for various prior art  
10 treatments for MS.

11 After tissue damage accumulates over many years, 50% of RRMS patients typically  
12 evolve to show Secondary Progressive MS (SPMS), in which pre-existing neurologic deficits  
13 gradually worsen over time and stop responding to standard MS therapies. So far, there are  
14 no immunomodulatory treatment available to stop or reverse this form of MS.

15 Primary Progressive (PPMS) affects about 15% of MS patients; these patients have  
16 gradually worsening manifestations from the onset without clinical relapses, patients with  
17 PPMS tend to be older, have fewer abnormalities on brain MRI, and generally do not respond  
18 to standard MS therapies. About 15% of patients have PPMS from the onset. So far, there are  
19 no immunomodulatory treatment available to stop or reverse this form of MS.

20 Progressive Relapsing (PRMS) entails gradual neurologic worsening from the onset  
21 with subsequent superimposed relapses. PPMS is suspected to represent SPMS, in which the  
22 initial relapses were unrecognized, forgotten, or clinically silent.

23 Interferon beta 1a, Interferon beta 1b and glatiramer acetate have failed to  
24 demonstrate efficacy in slowing down the disability progression. Therapies such as  
25 mitoxantrone, methotrexate, azathioprine and cyclophosphamide have poor methodological  
26 clinical studies where both RRMS patients are evaluated together with SP and PPMS  
27 patients, and do not show a reduction in the progression of disability. Finally, there is no  
28 evidence with natalizumab, fingolimod and teriflunomide; however, unpublished data would  
29 indicate no effect on the progressive forms. Therefore, current available drugs, including the  
30 disease modifying drugs used for RRMS, cannot reverse, halt or even slow down the  
31 progressive disability in the SP& PPMS forms.

32 Interferon beta-1a (IFNB-1a) has been tested for efficacy in Secondary progressive  
33 MS (SPMS). This testing included two clinical trials. The IMPACT study included a total of

436 subjects with Secondary progressive MS with relapses that were randomized to receive IFNB-1a weekly (intramuscular) or placebo for two years. The IMPACT data showed a significant benefit in the group of IFNB-1a in terms of MSFC decrease (40.4%,  $p=0.033$ ), fewer relapses (33%,  $p=0.008$ ), better outcome in eight of eleven MS Quality of Life scales and less MRI activity ( $p<0.001$ ).

The SPECTRIMS study included a total of 618 patients with Secondary progressive MS with relapses who received IFNB-1a (three times weekly) or placebo for 3 years. The data showed that IFNB-1a did not significantly affect disability progression ( $p=0.146$ ), although significant treatment benefit was observed on relapse rate (reduced from 0.71 to 0.50 per year,  $p<0.001$ ) and on MRI outcomes.

Interferon beta-1b (IFNB-1b) has also been tested for efficacy in Secondary progressive MS in two clinical trials. In the EUSPMS: a total of 718 patients with Secondary progressive MS were randomized to IFNB-1b or placebo with treatment duration of up to three years. The EUSPMS data showed that the time to confirmed 1.0 point progression on the Expanded Disability Status Scale (EDSS) was delayed ( $p=0.007$ ) and the progression of 2.0 EDSS point was 27% lower.

The NASPMS study included 939 subjects with Secondary progressive MS *with relapses* that were randomized to either placebo or IFNB-1b. The NASPMS data showed no treatment benefit on time to confirmed progression of disability, though relapse and MRI-related outcomes showed significant benefit. A combined analysis of both the EUSPMS and NASPMS trials shows that the patients with more pronounced disability progression and continuing relapse activity could be more likely to benefit from treatment.

For Primary progressive MS (PPMS), a Cochrane systematic review included two randomized controlled trials (entailing a total of 123 patients), and compared interferon treatment versus placebo in patients with PPSM. This review did not show differences regarding the proportion of patients with progression of the disease (RR 0.89, 95%CI 0.55 to 1.43), and it was associated with a greater frequency of treatment-related adverse events (RR 1.90, 95% CI 1.45-2.48). One of the trials showed a lower number of active MRI lesions at two years in interferon arm (difference -1.3, 95% CI -2.15 to -0.45,  $P=0.003$ ).

Glatiramer Acetate was tested in a controlled clinical trial (Wolinsky 2007) wherein a total of 943 patients with PPMS were randomized. The data showed there was a non-significant delay in time to sustained accumulated disability (hazard ratio, 0.87 [95% confidence interval, 0.71-1.07];  $p=0.1753$ ).

1 In La Mantia 2010 (the Cochrane systematic review), data for 1049 patients with  
2 Primary progressive MS contributed to the meta-analysis. No benefit was shown in SPMS  
3 and PPMS patients. No major toxicity was found. The most common systemic adverse event  
4 was a transient and self-limiting patterned reaction of flushing, chest tightness, sweating,  
5 palpitations, and anxiety. Local injection-site reactions were observed in up to a half of  
6 patients treated with glatiramer acetate, thus making a blind assessment of outcomes  
7 questionable.

8 Mitoxantrone was evaluated in Hartung (2002), describing a controlled clinical trial of  
9 194 patients with worsening RRMS or SPMS with relapses. Patients were assigned placebo  
10 or mitoxantrone; 188 patients completed the protocol and were able to be assessed at 24  
11 months. At 24 months, the mitoxantrone group experienced benefits compared with the  
12 placebo group on different clinical measures (difference 0.3 [95% CI 0.17-0.44];  $p < 0.001$ ),  
13 reducing progression of disability and clinical exacerbations.

14 Similarly, Martinelli (2005), the Cochrane systematic review, provides a meta-  
15 analysis of four clinical trials involving a total of 270 patients with RRMS, PRMS and SPMS  
16 with relapses. Meta-analysis showed that mitoxantrone reduced the progression of disability  
17 at 2 years follow-up (proportion of patients with 6-months confirmed progression of  
18 disability: Odds Ratios 0.3,  $p = 0.05$ ). These results, however, are based on heterogeneous  
19 trials in terms of drug dosage and inclusion criteria.

20 Cyclophosphamide was meta-evaluated in La Mantia (2007), a Cochrane systematic  
21 review. The meta-analysis included four RCTs comparing Cyclophosphamide to placebo or  
22 no treatment, entailing a total of 152 participants. The meta-analysis showed that  
23 cyclophosphamide did not prevent the long-term (12, 18, 24 months) clinical disability  
24 progression as defined as evolution to a next step of EDSS score. However, the mean change  
25 in disability (final disability subtracted from the baseline) significantly favoured the treated  
26 group at 12 (effect size - 0.21, 95% confidence interval - 0.25 to -0.17) and 18 months (-  
27 0.19, 95% confidence interval - 0.24 to - 0.14) but favoured the control group at 24 months  
28 (0.14, CI 0.07 to 0.21).

29 Methotrexate was studied in a trial with 60 progressive MS patients only. The results  
30 from Gray (2006) show there was a non-significant reduction in sustained EDSS progression  
31 and number of relapses in favour of methotrexate therapy. There were no data on relapse rate  
32 and no difference in time to first relapse. Minor side effects were reported in both  
33 methotrexate (87.1%) and placebo groups (89.7%), but there were no major side effects.

Rituximab was studied in 439 PPMS patients, randomized to intravenous rituximab or placebo. The data from Hawker (2009) showed differences in time to confirmed disease progression between rituximab and placebo did not reach significance (96-week rates: 38.5% placebo, 30.2% rituximab;  $p=0.14$ ). From baseline to week 96, rituximab patients had less ( $p<0.001$ ) increase in T2 lesion volume; brain volume change was similar ( $p=0.62$ ) to placebo. Adverse events were comparable between groups.

The Azathioprine Cochrane systematic review (Casetta (2007)) included 698 randomized patients with all clinical forms of MS. The pooled data showed azathioprine reduced the number of patients who had relapses during the first year of treatment (relative risk reduction [RRR] =20%; 95% CI = 5% to 33%), at two years (RRR =23%; 95% CI = 12% to 33%) and three years (RRR =18%; 95% CI = 7% to 27%) follow-up. These results were consistent in sensitivity analysis. There was no heterogeneity among the studies. Data from only three small trials with a total of 87 patients were available to calculate the number of patients who progressed during the first two to three years. There was a statistically significant benefit (RRR = 42%; 95% CI = 7% to 64%) of azathioprine therapy at three years' follow-up; this result was robust after sensitivity analyses.

The prior art thus teaches many potential therapies for MS. The art, however, also teaches that certain forms of MS remain resistant to any currently-known therapy.

Andrographolide (the claimed compound) and certain analogous compounds are taught by Juan Luis HANCKE et al., United States Letters Patent No. 8080495. That patent also teaches autoimmune diseases including "rheumatoid diseases, psoriasis, systemic dermatomycocytis, multiple sclerosis [and] lupus erythematosus." *See* 1:29-39. Regarding multiple sclerosis, the patent says, "Using the mixture of andrographolides described in Example 9, normalization in the symptoms of the disease occurs following 3 months of treatment of the composition of the present invention. In addition, the composition does not interfere with other treatments." *See* 18:10-15. The patent unfortunately does not expressly say what form of multiple sclerosis was there studied. Mention of "other treatments," however, means that the form of MS there studied must have been the only one which in fact has "other treatments," *i.e.*, relapsing-remitting form MS. This patent thus fails to expressly nor implicitly teach use of andrographolide to treat any progressive form of MS.

Further, the art teaches that every other treatment for relapsing-remitting MS is ineffective for progressive forms of MS. *See supra*. Thus, this prior art patent failed to provide the skilled artisan a reasonable expectation of success in using the claimed



1 compounds for any progressive form of MS.

2 Published PCT Application WO2013/096423 teaches the claimed compounds  
3 synergistically improve the efficacy of interferon in treating Multiple Sclerosis. *See* page 2 at  
4 Summary, page 8 at 7<sup>th</sup> paragraph. The art, however, teaches that interferons are not effective  
5 at all to treat progressive forms of MS. *See supra*. Thus, the skilled artisan would have read  
6 WO '423 to teach combining interferon with the claimed compounds to treat the relapsing-  
7 remitting form of MS, rather than a progressive form of MS. Similarly, the artisan would  
8 have read WO '423 to teach that interferon is an indispensable part of MS therapy.

#### 10 BRIEF SUMMARY

11 We have tested andrographolide in a controlled, randomized, double-blinded human  
12 clinical trial of andrographolide 140mg orally administered twice per day (*i.e.*, 280 mg per  
13 day) in patients with progressive forms of Multiple Sclerosis. The principle objective of that  
14 study was to determine efficacy, safety and tolerability of andrographolide in retarding the  
15 progression of brain atrophy. Secondary end-points included: delay in the disability capacity  
16 progression through the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis  
17 Funcional Composite (MSFC) at 24 months compared to the baseline; delay in cognitive  
18 impairment by means of Paced Auditory Serial Addition Test (PASAT), Symbol Digit  
19 Modalities Test (SDMT) and depression (Beck) at 24 months compared to the baseline;  
20 quality of life Multiple Sclerosis Impact Scale (MSIS 29) and fatigue (Krupp) through  
21 parameters reported by the patients at 24 months compared to the baseline; Tolerability of  
22 andrographolide measured by Magnetic Resonance (MR) at 24 months compared to baseline;  
23 Number and volume of new lesions or larger size in T2 by MR at 24 months compared to the  
24 baseline; Number of new hipointense lesions in T1 or (gadolinium captive) by MR at 24  
25 months compared to baseline; Delay in the retinal thinning measured by Optical Coherence  
26 Tomography (OCT) and visual field at 24 months compared to the baseline; and Safety of  
27 andrographolide at 24 months through the record of adverse effects in symptom diary and  
28 programmed interviews. The details of the study are described more completely in United  
29 States Provisional patent application Serial No. 62/347218 (filed 08 June 2016), incorporated  
30 here by reference.

#### 32 BRIEF DESCRIPTION OF THE DRAWINGS

33 Figure 1 shows *in vitro* results. (A) Lymph node cell suspensions obtained from

C57BL/6 and BALB/c mice were co-cultured with increasing concentrations of IB-MS for 72 h. After this time, supernatants were harvested and analyzed for IL-2 release by ELISA assay (circles) and T cell proliferation (squares) was determined by Cell Titer assay. (B) Mice treated with vehicle (solid circles) or andrographolide (empty circles) were MOG-immunized one week later and clinical score determined daily. These data indicate that IB-MS treatment interferes with T cell activation and prevents EAE.

Figure 2 shows the comparative effect between IB-MS and IFN- $\beta$ -treatment on three groups of MOG-immunized C57BL/6J mice (150 ug MOG-peptide; 500 ug MT; 200 ng PT) were treated every second day with PBS (black triangles), IFN- $\beta$  (purple squares) or 4 mg/kg IB (blue circles) at the beginning of chronic phase (day 15 post-immunization) until day 30 post-immunization. These data indicate that IB-MS has a therapeutic effect in EAE.

Figure 3 shows inflammatory infiltrate and demyelination is reduced in spinal cord of AG-treated mice. MOG-immunized C57BL/6J mice (150 ug MOG-peptide; 500 ug MT; 200 ng PT) were treated daily with 4 mg/kg andrographolide. Animals were treated at the beginning of chronic phase (day 15 post-immunization) until day 20 post-immunization. As controls MOG-immunized C57BL/6J mice were injected with vehicle (PBS) daily. At day 21 p.i. mice were sacrificed. MOG-immunized mice treated with either PBS (A-C) or AG (B-D) were perfused and 4 % p-formaldehyde fixed. Toracic spinal cords sections were dissected and analyzed for inflammatory infiltrate by hematoxylin-eosin staining (H&E) and for demyelination with luxol fast blue staining (LFB). Insets show higher magnification (20X).

Figure 4 illustrates the process flowchart for our 12-month pilot clinical study.

Figure 5 lists certain secondary outcomes and provides the study timeline.

Figure 6 presents the effect of *IB-MS* on Expanded Disability Status Scale (EDSS) in patients with progressive MS.

Figure 7 presents the effect of *IB-MS* on the Nine Hole Pin Test (9HPT) (L=left handed; R=right handed) in patients with progressive MS.

Figure 8 presents effect of *IB-MS* on a 25-Foot Walk Test (25FWT) in patients with progressive MS.

Figure 9 presents a schematic diagram of possible mechanisms of action at the cellular level of our invention (AP = andrographolide).

Figure 10 shows the effect of andrographolide (A) on 9-HPT in human patients. The numbers (x axis) on the figure are measurements 6: corresponds to 2 year treatment. There are still many patients that need to complete the 2 year treatment. The data therefore show a

lot of variance. Despite that, we can see that the treated patients are more skilled and more quickly complete the task of upper extremity function. The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It is the second component of the MSFC to be administered at each visit. Both the dominant and non-dominant hands are tested twice. The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. On a start command when a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand.

Figure 11 shows MSIS 29 scale results for human patients. In control group (b) one can see that the patients after 2 years as compared to day 0, the percentage goes from 95 to 75, meaning a physical & psychological deterioration. In the treatment group (a), the percentage goes from 80 to 90. Preliminarily, it shows that the treatment patients maintain or slightly improve their scores.

#### DETAILED DESCRIPTION

The details of our clinical study are described in United States Provisional patent application Serial No. 62/347218 (filed 08 June 2016), incorporated here by reference. While that study was designed as a 24-month study, interim results after only 12 months of treatment show statistically-significant efficacy. Our interim results show that in the treatment of Secondary Progressive (SP) and Primary Progressive (PP) forms of Multiple Sclerosis (MS), remyelination, and neurogenesis are stimulated by oral administration of andrographolide-class compounds.

There are 3 components of the Multiple Sclerosis Functional Composite (MSFC) disease activity index: function of the legs, function of the arms and cognitive function. The corresponding tests are a 25 foot (7.6 m) walk; test of 9 holes and pin and the Paced Auditory Serial Addition test 3 (PASAT3). Multiple attempts will be made of each test in each visit. The MSFC score and the scores of the 3 sub-scales and the change from the basal values will be recorded in each visit.

One measure of progressive MS disease severity is the Expanded Disability Status

1 Scale (EDSS). EDSS is a scale to determine the neurological disability in MS and is used to  
2 confirm progression of the disease. It consists of a system of two parts. The first part  
3 measures eight functional systems (FS). The second part measures disability on a scale of 1  
4 to 10, zero being no disability and 10 being death due to MS.

5 Literature shows that in non-treated MS patients, the evaluated disability by EDSS  
6 increases one point in the 15% of the subjects after 2 years of follow up (Kragt *et al*, 2010).  
7 The size of the sample in order to evaluate a reduction in 50% of this parameter is expected in  
8 the intervened group, 7.5% of the subjects increases one point in the disability scale. In order  
9 to find differences with a level of significance of 0.05 and a potency of 0.80, it will be  
10 necessary to evaluate 28 subjects per group. Considering also that one intervened subjects  
11 for each control and a 20% percentage of drop off, the total number of subjects to evaluate is  
12 68. To find differences with a level of significance of 0.05 and a potency of 0.80 it is  
13 necessary to evaluate 28 subjects per group. Considering also one intervened subject for each  
14 control and a 20% “drop off”, the total number to evaluate is 68.

15 Our results for 12 months of treatment are provided in Figure 6. Figure 6 shows that  
16 treatment provides an improvement *viz* placebo which becomes statistically-significant by  
17 nine months and more significant by twelve months of treatment.

18 The Nine Hole Pin Test (9HPT) is a component of the MS Functional Composite  
19 (MSFC) score. 9HPT is a timed test measuring the time (seconds) required to insert each of  
20 nine pins into nine holes in a plank. The test is done on each of the right and left arms. The  
21 test measures eye-hand coordination and fine muscle control. Our results for twelve months  
22 of treatment are provided in Figure 7. Results for the right hand test (9HPT-R) show  
23 treatment provides an improvement (reduction) in time required to complete the test, which  
24 improvement becomes statistically significant by twelve months of treatment. The data for  
25 the left hand test (9HPT-L) confirm this improvement, yet curiously shows the improvement  
26 becomes statistically significant almost immediately and grows in significance over twelve  
27 months. Note that in comparing the left and right hand data, the vertical (time) scale for the  
28 left hand test is compressed. This is because the left hand is generally non-dominant, thus  
29 requiring systematically longer times to completion.

30 Another measure of coordination is the 25-Foot Walk Test (25FWT). The 25FWT  
31 measures the time (seconds) required to walk a distance of 7.6 meters (25 feet). Literature  
32 shows that in non-treated MS patients, disability evaluated by time (seconds) (time a patient  
33 takes to cover a distance of 25 feet), increases one point in 45% of the subjects (Kragt *et al*,


2010). Sample size was calculated to evaluate a reduction in 50% in this parameter (that is, it is expected that in the intervened group a 22.5% of the subjects increases one point in the disability scale). In order to find a difference in the level of significance of 0.05 and a potency of 0.80 it is necessary to evaluate 68 subjects per group. Considering also one intervened subject for each control and a 20 % of drop off, the total number of subjects to evaluate is 68. In order to find a difference with a level of significance of 0.05 and a potency of 0.43, it is necessary to evaluate 28 subjects per group. Considering also one intervened subjects for each control and a 20% drop off, the total subjects to evaluate is 68.

Our preliminary data in Figure 8 show that treatment provides an improvement (reduction) in time required to complete the test viz placebo, which improvement becomes statistically significant immediately on commencement of treatment and persists for twelve months of treatment.

Thus, an object of the present invention is to provide pharmaceutical compositions for treating Secondary Progressive (SP) and Primary Progressive (PP) forms of Multiple Sclerosis (MS), comprising oral administration of andrographolide and or analogues thereof, optionally including one or more pharmaceutically-acceptable excipients and/or carriers.

Another object of the present invention is, therefore, to provide a method of treating a subject suffering from SPMS and PPMS and/or another demyelinating disease, the method consisting of administering the pharmaceutical compositions of the invention to the subject in an effective amount and for a time sufficient to produce remyelination and neurogenesis.

The present invention provides pharmaceutical compositions for treating SPMS and PPMS forms and/or other demyelinating diseases, comprising a compound of Formula (I):



(I)

wherein

R<sub>1</sub> is selected from the group consisting of hydrogen, alkyl or hydroxyl,

$R_2$  is selected from the group consisting of hydroxyalkyl or alkyl-O- $L_1$ , wherein  $L_1$  is a carbohydrate moiety,

$R_3$  is selected from the group consisting of hydrogen or hydroxyl,

$X$  is selected from the group consisting of  $C(=CH_2)$ ,  $CH(OH)$ , or a 2,2-dimethyloxirane;

$Z$  is selected from the group consisting of  $CH_2$ ,  $CH(OH)$  or  $C(=O)$ , and

$R_4$  is selected from the group consisting of an optionally substituted  $L_2$ -alkyl or  $L_2$ -alkenyl, wherein  $L_2$  is an optionally substituted 3-furanyl or 3-fur-3-enyl moiety,



or a pharmaceutically acceptable salt, ester, ether or prodrug thereof, and one or more pharmaceutically acceptable excipients and/or carriers.

In one embodiment,  $R_1$  is methyl.

In another embodiment,  $R_2$  is hydroxymethyl or  $CH_2$ -O-Glc, wherein Glc is a glycoside-forming glucose moiety.

In another embodiment,  $R_4$  is optionally substituted 3-(3-furanyl)-propyl, 3-(3-furanyl)-prop-1-enyl, 3-(3-furanyl)-prop-2-enyl, 3-(3-fur-3-enyl)-propyl or 3-(3-fur-3-enyl)-prop-1-enyl wherein the 3-furanyl or the 3-fur-3-enyl moieties are further optionally substituted.

In one embodiment,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $X$  and  $Z$  are those described above, and  $R_4$  is selected from the group consisting of:



wherein:

R<sub>5</sub> is selected from the group consisting of hydrogen or hydroxyl,


R<sub>6</sub> and R<sub>7</sub> are independently selected from the group consisting of hydrogen, hydroxyl, or alkyloxy, or R<sub>6</sub> and R<sub>7</sub> are simultaneously replaced by a single direct bond between the carbon atoms denoted by \*, thus forming a dimer of two monomer molecules of formula (I), and R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of hydrogen, hydroxyl or alkyloxy.

In one embodiment, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> or R<sub>9</sub> can be independently methoxy.

In preferred embodiments, the compounds of Formula (I) are selected from the group consisting in andrographolide, neoandrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-didehydroandrographolide, andrographiside, andrograpanin, 14-deoxy-11-oxo-andrographolide, 14-deoxy-11-hydroxy-andrographolide, 14-deoxy-12-hydroxy-andrographolide, 3,14-dideoxyandrographolide, 3-oxo-14-deoxyandrographolide, 8,17-epoxy-14-deoxyandrographolide, 14-deoxy-17-beta-hydroxyandrographolide, 12-hydroxyandrographolide, bisandrographolide A, 3-oxo-14-deoxy-11,12-didehydroandrographolide, 7-hydroxy-14-deoxyandrographolide, 15-methoxy-3,19-dihydroxy-8(17)11,13-ent-labda-trien-16,15-olide, andropanolide, 14-deoxy-12-methoxy-andrographolide, 14-epi-andrographolide, 19-hydroxy-ent-labda-8(17),13-dien-15,16-olide, 3,13,14,19-tetrahydroxy-ent-labda-8(17),11-dien-16,15-olide, 3,19-dihydroxy-15-methoxy-ent-labda-8(17),11,13-trien-16,15-olide, and 3,19-dihydroxy-ent-labda-8(17),12-dien-16,15-olide.

For example, our invention entails treating a progressive form of MS by administering andrographolide without accompanying interferon. Alternatively, one may combine andrographolide with interferon.

Andrographolide (or AP) is the principal active component responsible for most of the biological activities attributed to *Andrographispaniculata*, a medicinal plant traditionally used in Asian countries such as China, India, Malaysia for the treatment of common cold, dysentery, fever, amygdalitis, hepatic diseases (Panossian, Davtyan et al. 2002; C. Patarapanich 2007; S. K. Mishra 2007). The traditional use and pharmacological studies of *Andrographispaniculata* have been previously well documented (Nemoto 2008).



Andrographolide

AP is a diterpene lactone that is present mainly in the leaves, relatively easily to extract whose molecular structure has been determined (A. B. Smith III 1982). This compound has a manifold of biological effects including cytotoxic effect in tumoral cells, anti-angiogenic, anti-inflammatory and immune modulating effects. AP inhibits selectively the proliferation of different types of tumoral cells (Cheung, Cheung et al. 2005; Kim, Hwi et al. 2005; Zhou, Zhang et al. 2006; Geethangili, Rao et al. 2008; Shi, Lin et al. 2008; Wang 2008; Zhao, He et al. 2008; Zhou, Lu et al. 2008; Yang, Wu et al. 2009), by means of inducing apoptosis, necrosis, through the induction of apoptosis, necrosis, arrest cell cycle or cell differentiation and suppression of angiogenic factors such as the endothelial vascular growth factor (VEGF) and inhibitor of metalloproteinases (TIMP-1) (Sheeja, Guruvayoorappan et al. 2007). For this reason, AP has the potential as an agent for the treatment (Rajagopal, Kumar et al. 2003; Jada, Subur et al. 2007) and HIV infection (Calabrese, Berman et al. 2000). Clinically, AP has demonstrated efficacy in Rheumatoid Arthritis (Burgos, Hancke et al. 2009), some types of cancer (See, Mason et al. 2002) and common cold (Caceres, Hancke et al. 1997).

One of the potent effects of AP is its anti-inflammatory and immune modulatory activity. AP has the capacity to induce a significant stimulation of the protective immune response *in vivo* against infectious and oncogenic agents (Puri, Saxena et al. 1993; Kumar, Sridevi et al. 2004; Khan 2007). Among the anti-inflammatory effect, there is a decrease in the production of oxygen reactive molecules, the inhibition of the expression of pro-inflammatory enzymes and enzymes such as COX-2 and iNOS (Chiou, Lin et al. 1998; Chiou, Chen et al. 2000) and inhibition of the activation transcriptional factor NF- $\kappa$ B (Wang, Liu et al. 2004; Xia, Ye et al. 2004; Hidalgo, Romero et al. 2005; Iruretagoyena, Tobar et al. 2005).

In a mice model, we have previously demonstrated that AP decreases: 1) the



1 maturation of dendritic cells and its capacity to present antigens to T cells, interfering with  
2 the activation of the transcription factor NF- $\kappa$ B (Hidalgo, Romero et al. 2005); 2) the process  
3 of activation of Jurkat cell line (lymphom of T cells) though the inhibition of the activation of  
4 the transcription factor NFAT and transductions signals pathways MAPK-Erk 1/2 (Carretta,  
5 Alarcon et al. 2009). Besides, AP could have an effect on neurodegeneration mediated by  
6 inflammation, since AP reduces reactive oxygen species, TNF- $\alpha$ , nitric oxide and  
7 prostaglandins E<sub>2</sub> in microglia (Wang, Liu et al. 2004). The anti-inflammatory and immune  
8 modulatory of AP has been demonstrated in inflammatory diseases *in vivo* in different  
9 models such as arthritis (Burgos, Hancke et al. 2009), lupus and asthma (Kalogris,  
10 Iruretagoyena et al. 2009). In a EAE model, we have reported that the prophylactic  
11 administration of AP prevents the development Of EAE through the inhibition of T and B  
12 cells response against myelin antigens (Iruretagoyena, Tobar et al. 2005). Many clinical  
13 studies have shown that AP is well tolerated and safe.


14       Considering the anti-inflammatory and immune modulatory antecedents of AP and  
15 the molecular basis that underlie the inflammatory process of MS, we postulate that this  
16 compound is a potential treatment for MS.

17       Given our disclosure here, the artisan can readily derive variants of it. For example,  
18 Figure 9 presents a schematic diagram of possible mechanisms of action and cellular level  
19 binding sites of andrographolide. The artisan may thus employ analogs of andrographolide  
20 which provide a similar mechanism of action, to produce similar effects. Alternatively, the  
21 artisan may vary the dosage amount to provide an equivalent therapeutic effect. While our  
22 actual experiments used solid tablets, hard gelatin capsules, liquid extracts and other oral  
23 dosage forms would be expected to function equivalently. We thus intend the legal coverage  
24 of our patent to be defined not by our specific examples, but by the legal claims appended  
25 here as approved by The Patent Office, and legally-permissible equivalents thereof.

## CLAIMS

I claim:

1. An oral dosage form comprising a compound of Formula (I):



wherein

R<sub>1</sub> is selected from the group consisting of hydrogen, alkyl or hydroxyl,



R<sub>2</sub> is selected from the group consisting of hydroxyalkyl or alkyl-O-L<sub>1</sub>, wherein L<sub>1</sub> is a carbohydrate moiety,

R<sub>3</sub> is selected from the group consisting of hydrogen or hydroxyl,

X is selected from the group consisting of C(=CH<sub>2</sub>), CH(OH), or a 2,2-dimethyloxirane,

Z is selected from the group consisting of CH<sub>2</sub>, CH(OH) or C(=O), and

R<sub>4</sub> is selected from the group consisting of:



wherein:

R<sub>5</sub> is selected from the group consisting of hydrogen or hydroxyl,

R<sub>6</sub> and R<sub>7</sub> are independently selected from the group consisting of hydrogen, hydroxyl, or alkyloxy, or R<sub>6</sub> and R<sub>7</sub> are simultaneously replaced by a single direct bond between the

carbon atoms denoted by \*, thus forming a dimer of two monomer molecules of Formula (I),  
and

R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of hydrogen, hydroxyl or alkyloxy,

or a pharmaceutically acceptable salt or ester thereof;

said oral dosage form providing an amount of said compound of Formula I effective to slow the progression of a Progressive form of multiple sclerosis in a human patient diagnosed with Progressive multiple sclerosis.

2. The oral dosage form of claim 1, wherein said amount effective comprises about 240 mg of said compound per day.

3. The oral dosage form of claim 1, wherein said amount effective is effective to slow progression of said Progressive form of multiple sclerosis as measured using an assay comprising an assay selected from the group consisting of: the Expanded Disability Status Scale, the 9-Hole Pin Test, the 25-Foot Walk Test and the Multiple Sclerosis Functional Composite index.

4. The oral dosage form of claim 1, wherein said progressive form of multiple sclerosis is selected from the group consisting of: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis and Progressive Relapsing Multiple Sclerosis.

5. The oral dosage form of claim 1, wherein said compound of Formula (I) comprises a compound selected from the group consisting of: andrographolide, neoandrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-didehydroandrographolide, andrographiside, andrograpanin, 14-deoxy-11-oxo-andrographolide, 14-deoxy-11-hydroxy-andrographolide, 14-deoxy-12-hydroxy-andrographolide, 3,14-dideoxyandrographolide, 3-oxo-14-deoxyandrographolide, 8,17-epoxy-14-deoxyandrographolide, 14-deoxy-17-beta-hydroxyandrographolide, 12-hydroxyandrographolide, bisandrographolide A, 3-oxo-14-deoxy-11,12-didehydroandrographolide, 7-hydroxy-14-deoxyandrographolide, 15-methoxy-3,19-dihydroxy-8(17),11,13-ent-labda-trien-16,15-olide, andropanolide, 14-deoxy-12-methoxy-andrographolide, 14-epi-andrographolide, 19-hydroxy-ent-labda-8(17),13-dien-15,16-olide, 3,13,14,19-tetrahydroxy-ent-labda-8(17),11-dien-16,15-olide, 3,19-dihydroxy-15-methoxy-ent-labda-8(17),11,13-trien-16,15-olide and 3,19-dihydroxy-ent-labda-8(17),12-dien-16,15-olide.

6. A method of treating a human patient comprising:

a. diagnosing in said human patient a Progressive form of multiple sclerosis, and then

- 1 b. administering the oral dosage form of Claim 1.
- 2 7. The method of claim 6, further comprising: administering interferon to said patient.
- 3
- 4
- 5

Figure 1A




Figure 1B




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4






FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




Figure 10




FIGURE 11

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/36463

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC(8) - A61K 31/365, A61K 36/19 (2017.01)  
 CPC - A61K 31/365, A61K 36/19, A61K 31/7028

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2014/0301981 A1 (Orozco et al.) 09 October 2014 (09.10.2014); Title, p7, para[0001], para[0010], para[0016], para[0020], para[0037], Claim 12, Claim 19, Claim 24	1-7
A	Bethoux et al. 'Evaluating Walking in Patients with Multiple Sclerosis', International Journal of MS Care, 22 October 2014 (22.10.2014), Vol.16, page153-160; Abstract	3
A	US 2006/0063831 A1 (Orozco et al.) 23 March 2006 (23.03.2006); entire document	1-7

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

03 August 2017 (03.08.2017)

Date of mailing of the international search report

06 SEP 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
 P.O. Box 1450, Alexandria, Virginia 22313-1450  
 Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300  
 PCT OSP: 571-272-7774